• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤微环境对非小细胞肺癌中白细胞介素-1β阻断效果的影响：来自CANOPY-1和CANOPY-N试验的生物标志物分析

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

作者信息

Solomon Benjamin J, Tan Daniel S W, de Castro Gilberto, Cobo Manuel, Garassino Marina Chiara, Zhang Jun, Johnson Bruce E, Lee Jay M, Garrido Pilar, Butler Andrew A, Pelletier Marc R, Savchenko Alexander, Ji Lexiang, Brase Jan C, Caparica Rafael, Demanse David, Wu Jincheng, Bossen Claudia, Mok Tony

机构信息

Peter MacCallum Cancer Centre, Melbourne, Australia.

National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore.

出版信息

Cancer Res Commun. 2025 Apr 1;5(4):632-646. doi: 10.1158/2767-9764.CRC-24-0490.

DOI:10.1158/2767-9764.CRC-24-0490
PMID:40116353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12006968/
Abstract

Patients with NSCLC with immunosuppressive tumor features and low T-cell infiltration derive less benefit from ICI-based treatment. Biomarker analyses presented here suggest that these patients may benefit from the addition of anti-IL-1β therapy to their treatment.

摘要

具有免疫抑制肿瘤特征且T细胞浸润低的非小细胞肺癌患者从基于免疫检查点抑制剂的治疗中获益较少。此处展示的生物标志物分析表明，这些患者可能会从在其治疗中添加抗白细胞介素-1β疗法中获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/442a68a9e40f/crc-24-0490_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/96409e1aa367/crc-24-0490_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/68446096ce06/crc-24-0490_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/c070da495d50/crc-24-0490_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/7e6d5d1e7426/crc-24-0490_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/c4c44b001b54/crc-24-0490_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/442a68a9e40f/crc-24-0490_f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/96409e1aa367/crc-24-0490_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/68446096ce06/crc-24-0490_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/c070da495d50/crc-24-0490_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/7e6d5d1e7426/crc-24-0490_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/c4c44b001b54/crc-24-0490_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/12006968/442a68a9e40f/crc-24-0490_f6.jpg

相似文献

1
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.肿瘤微环境对非小细胞肺癌中白细胞介素-1β阻断效果的影响：来自CANOPY-1和CANOPY-N试验的生物标志物分析
Cancer Res Commun. 2025 Apr 1;5(4):632-646. doi: 10.1158/2767-9764.CRC-24-0490.
2
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.可切除非小细胞肺癌患者接受卡那单抗联合和不联合帕博利珠单抗治疗的研究：CANOPY-N 研究设计。
Future Oncol. 2021 Apr;17(12):1459-1472. doi: 10.2217/fon-2020-1098. Epub 2021 Mar 2.
3
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.肿瘤微环境在肺癌中的治疗意义：聚焦免疫检查点阻断。
Front Immunol. 2022 Jan 7;12:799455. doi: 10.3389/fimmu.2021.799455. eCollection 2021.
4
LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.在非小细胞肺癌中，LKB1通过Skp2介导的PD-L1蛋白泛素化决定对免疫疗法的敏感性。
J Immunother Cancer. 2024 Dec 18;12(12):e009444. doi: 10.1136/jitc-2024-009444.
5
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer.在PD-L1高表达的肺癌中，细胞内源性PD-L1信号通过IL-6/Jak/Stat3途径驱动髓源性抑制细胞产生免疫抑制作用。
J Immunother Cancer. 2025 Mar 6;13(3):e010612. doi: 10.1136/jitc-2024-010612.
6
AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.AXL 表达反映了影响免疫检查点抑制剂单药治疗的非小细胞肺癌患者结局的肿瘤免疫细胞动态。
Front Immunol. 2024 Aug 21;15:1444007. doi: 10.3389/fimmu.2024.1444007. eCollection 2024.
7
Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.在人源肺癌组织中，通过检查点抑制激活固有免疫。
Elife. 2021 Aug 18;10:e69578. doi: 10.7554/eLife.69578.
8
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与含或不含贝伐珠单抗的一线含铂化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2.
9
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
10
Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition.联合抑制IL-1β和PD-1以克服肺癌中的免疫抑制和促肿瘤炎症
Future Oncol. 2022 Sep;18(27):3085-3100. doi: 10.2217/fon-2021-1567. Epub 2022 Aug 25.

引用本文的文献

1
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.利用临床和真实世界数据定义原发性和获得性免疫检查点抑制剂耐药时非小细胞肺癌肿瘤微环境的变化
Cancer Res Commun. 2025 Jun 1;5(6):1049-1059. doi: 10.1158/2767-9764.CRC-24-0605.

本文引用的文献

1
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.卡那单抗联合多西他赛对比多西他赛单药治疗铂类双药化疗和免疫治疗后进展期非小细胞肺癌（CANOPY-2）：一项多中心、随机、双盲、III 期临床试验。
Lung Cancer. 2024 Mar;189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16.
2
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.卡那单抗联合一线帕博利珠单抗加化疗对比安慰剂治疗晚期非小细胞肺癌：CANOPY-1试验结果
J Clin Oncol. 2024 Jan 10;42(2):192-204. doi: 10.1200/JCO.23.00980. Epub 2023 Dec 1.
3
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.卡那单抗作为完全切除的非小细胞肺癌患者的辅助治疗：CANOPY-A双盲随机临床试验结果
J Clin Oncol. 2024 Jan 10;42(2):180-191. doi: 10.1200/JCO.23.00910. Epub 2023 Oct 3.
4
Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.基于随机对照试验的 PD-L1 表达对 PD-1/L1 抑制剂治疗非小细胞肺癌效果的 Meta 分析。
Clin Oncol (R Coll Radiol). 2023 Oct;35(10):640-651. doi: 10.1016/j.clon.2023.07.012. Epub 2023 Jul 31.
5
Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.全面综述：揭示 IL-1ß 和 PD-1/PD-L1 在 NSCLC 发展中的致癌作用，并针对其通路进行临床管理。
Int J Mol Sci. 2023 Jul 17;24(14):11547. doi: 10.3390/ijms241411547.
6
Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.关于肿瘤免疫微环境、其异质性以及晚期非小细胞肺癌治疗未来展望的当前文献综述。
Transl Lung Cancer Res. 2023 Apr 28;12(4):857-876. doi: 10.21037/tlcr-22-633. Epub 2023 Mar 17.
7
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.针对 IL1β 通路的癌症免疫疗法重塑肿瘤微环境并增强抗肿瘤免疫反应。
Cancer Immunol Res. 2023 Jun 2;11(6):777-791. doi: 10.1158/2326-6066.CIR-22-0290.
8
Lung adenocarcinoma promotion by air pollutants.空气污染促进肺腺癌。
Nature. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5.
9
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
10
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.